https://www.selleckchem.com/pr....oducts/sar439859.htm
Estimates on the distribution of patients with multiple myeloma (MM) by line of therapy (LOT) are scarce and get outdated quickly as new treatments become available. The objective of this study was to estimate the number of patients with MM by LOT and the number of patients who have received at least 4 previous LOTs including proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies (mAbs). A compartmental model was developed to calculate the number of patients by LOT. Two pathways were considered based on st
Like
Comment
Share
